Related Experiment Video

Updated: Jan 24, 2026

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease
06:39

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Published on: February 18, 2020

7.2K

LncRNA-MIAT Increased in Patients with Coronary Atherosclerotic Heart Disease

Jin Tan1, Shengzhong Liu1, Qin Jiang1

  • 1Cardiovascular Surgery Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu 610000, China.

Cardiology Research and Practice
|May 31, 2019
PubMed

Insights

Serum levels of long noncoding RNA-MIAT (lncRNA-MIAT) are elevated in patients with coronary atherosclerotic heart disease (CAD). This finding suggests lncRNA-MIAT may serve as a diagnostic and prognostic biomarker for CAD.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cardiology

Background:

  • Coronary atherosclerotic heart disease (CAD) poses a significant global health challenge.
  • Understanding the molecular mechanisms underlying CAD is crucial for developing effective diagnostic and therapeutic strategies.

Purpose of the Study:

  • To investigate the expression levels of long noncoding RNA-MIAT (lncRNA-MIAT) in patients with CAD.
  • To determine the clinical significance and potential role of lncRNA-MIAT as a biomarker in CAD.

Main Methods:

  • Serum samples were collected from 106 CAD patients and 89 healthy controls.
  • Quantitative analysis was performed to measure serum levels of lncRNA-MIAT, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α).
  • Statistical analyses, including correlation and multivariate analyses, were employed to assess the relationships between these markers and CAD risk factors.

Main Results:

  • Serum lncRNA-MIAT levels were significantly higher in CAD patients compared to healthy individuals.
  • Serum MIAT expression showed a positive correlation with serum IL-6 and TNF-α levels in CAD patients.
  • Multivariate analysis identified hypertension, diabetes, HDL-C levels, and serum MIAT expression as independent risk factors for CAD.

Conclusions:

  • Elevated serum lncRNA-MIAT is a characteristic feature of CAD.
  • Serum lncRNA-MIAT may function as a potential diagnostic and prognostic biomarker for coronary atherosclerotic heart disease.
Abstract

More Related Videos

Analysis of Coronary Vessels in Cleared Embryonic Hearts08:25

Analysis of Coronary Vessels in Cleared Embryonic Hearts

Published on: December 7, 2016

8.6K
Author Spotlight: Innovative Technique for Coronary Angiography in Marginal Donors06:25

Author Spotlight: Innovative Technique for Coronary Angiography in Marginal Donors

Published on: July 12, 2024

837

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.6K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
934
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
400
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
230
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
471